Carfilzomib

被引：162
作者：
Kortuem, K. Martin [1 ]
Stewart, A. Keith [1 ]
机构：
[1] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA
来源：
BLOOD | 2013年 / 121卷 / 06期
关键词：
UNFOLDED PROTEIN RESPONSE; SINGLE-AGENT CARFILZOMIB; PROTEASOME INHIBITOR CARFILZOMIB; REFRACTORY MULTIPLE-MYELOMA; 20 S PROTEASOME; ENDOPLASMIC-RETICULUM; OPEN-LABEL; BORTEZOMIB RESISTANCE; SELECTIVE INHIBITORS; THERAPEUTIC TARGET;
D O I：
10.1182/blood-2012-10-459883
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. This review focuses on clinical trial data leading to drug approval and provides advice for treating physicians who are now accessing this drug for patients. (Blood. 2013;121(6):893-897)
引用
收藏
页码：893 / 897
页数：5
相关论文
共 79 条
  • [1] Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
    Adams, J
    Behnke, M
    Chen, SW
    Cruickshank, AA
    Dick, LR
    Grenier, L
    Klunder, JM
    Ma, YT
    Plamondon, L
    Stein, RL
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) : 333 - 338
  • [2] Alsina M, 2011, AAPS J, V13, pT2419
  • [3] A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
    Alsina, Melissa
    Trudel, Suzanne
    Furman, Richard R.
    Rosen, Peter J.
    O'Connor, Owen A.
    Comenzo, Raymond L.
    Wong, Alvin
    Kunkel, Lori A.
    Molineaux, Christopher J.
    Goy, Andre
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4830 - 4840
  • [4] [Anonymous], BLOOD
  • [5] [Anonymous], J CLIN ONCOL S
  • [6] Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation
    Arendt, CS
    Hochstrasser, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (14) : 7156 - 7161
  • [7] IDENTITY OF THE 19S PROSOME PARTICLE WITH THE LARGE MULTIFUNCTIONAL PROTEASE COMPLEX OF MAMMALIAN-CELLS (THE PROTEASOME)
    ARRIGO, AP
    TANAKA, K
    GOLDBERG, AL
    WELCH, WJ
    [J]. NATURE, 1988, 331 (6152) : 192 - 194
  • [8] BADROS AZ, 2010, ASCO M S, V28, P8128
  • [9] Badros AZ, 2009, BLOOD, V114, P3877
  • [10] The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition
    Bianchi, Giada
    Oliva, Laura
    Cascio, Paolo
    Pengo, Niccolo
    Fontana, Francesca
    Cerruti, Fulvia
    Orsi, Andrea
    Pasqualetto, Elena
    Mezghrani, Alexandre
    Calbi, Valeria
    Palladini, Giovanni
    Giuliani, Nicola
    Anderson, Kenneth C.
    Sitia, Roberto
    Cenci, Simone
    [J]. BLOOD, 2009, 113 (13) : 3040 - 3049
12345678